Pharmacyclics (PCYC +8.5%) soars as positive data is released on its phase II study of the...
Pharmacyclics (PCYC +8.5%) soars as positive data is released on its phase II study of the potential blockbuster Btk inhibitor. The stock's a blockbuster itself, up nearly 60% since hitting a 52-week low in early March.
From other sites
at CNBC.com (Jan 13, 2015)
at CNBC.com (Dec 5, 2014)
at CNBC.com (Sep 17, 2014)
at CNBC.com (Jul 29, 2014)
at CNBC.com (Jul 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs